ArticleJournal of the American Heart Association2025
Prognostic Value of Baseline and Soluble ST2 Change in Patients With Light Chain Cardiac Amyloidosis.
Anran Xin, Xinqing Li, Yan Huang, Qiong Zhou, Xiaofeng Zhuang, Huihui Liu, Ping Zhou, Jinxi Wang, Xuemei Zhao, Jian Zhang and 1 more
Abstract read
In one paragraphArticle in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Anran XinHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.
Xinqing LiHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.
Yan HuangHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.
Qiong ZhouHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.
Xiaofeng ZhuangHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.
Huihui LiuHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.
Ping ZhouHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.ORCID 0000-0003-1909-0248 Jinxi WangHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.
Xuemei ZhaoHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.ORCID 0000-0003-0748-8777 Jian ZhangHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.ORCID 0000-0002-5093-4325 Yuhui ZhangHeart Failure Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) Beijing China.ORCID 0009-0000-7477-5712 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
backgroundThe prognostic significance of dynamic changes in soluble suppression of tumorigenicity-2 (sST2) in patients with light chain cardiac amyloidosis (AL-CA) remains unclear. We aimed to evaluate the prognostic significance of both baseline sST2 and 30-day changes (ΔsST2) in patients with light chain cardiac amyloidosis.
methodsPatients diagnosed with light chain cardiac amyloidosis in Heart Failure Center, Fuwai Hospital (October 2015-May 2024) were enrolled in the entire cohort, with baseline sST2 measured. A prospective subcohort (October 2023-May 2024) also underwent 30-day repeat sST2 measurement. ΔsST2 was defined as the sST2 level at 30 days minus baseline sST2. The primary outcome was all-cause mortality. Prognostic value of both baseline and ΔsST2 was assessed using Kaplan-Meier and Cox models. The relationships between variables and primary outcome were examined with restricted cubic splines.
resultsIn the entire cohort with 172 patients included (mean age 60.35±10.21 years; 40.1% women; median follow-up 310 days), higher baseline sST2 levels (>35 ng/mL) were independently associated with increased all-cause mortality risk (adjusted hazard ratio [HR], 1.82 [95% CI, 1.13-2.91],
conclusionsElevated baseline sST2 (>35 ng/mL) and short-term increases in sST2 predict poor prognosis in patients with light chain cardiac amyloidosis.
Indexed as
CardiomyopathiesImmunoglobulin Light-chain AmyloidosisInterleukin-1 Receptor-Like 1 ProteinAgedBiomarkersFemaleHumansMaleMiddle AgedPrognosisProspective StudiesRisk FactorsTime FactorsBiomarkersIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 Proteinbiomarkercardiac amyloidosisprognosissoluble ST2
Identifiers
PMID41334729
PMCPMC12826881
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390